Dr David Holbrook, healthcare venture capitalist for over 20 years, joins the investment team at RYSE Asset Management

We’re thrilled that Dr David Holbrook has joined us in our mission to build a global digital future for healthcare!

David is one of the leaders in the field of UK university technology spinouts and investment. As a qualified doctor, and after senior roles at GSK and Roche, he headed up Imperial’s spinout incubator, the medtech investing strategy at MTI, and Seed Fund at LifeArc (formerly Medical Research Council Technologies).

He was an early advocate of the convergence of the technology and life sciences sectors, including investment in ApaTech – a bone graft company sold to Baxter International Inc. for $300m. He is also a director of AIM-listed healthcare company Oxford BioDynamics Plc and senior independent director at The Worldwide Healthcare Trust plc.

David holds degrees from the University of Oxford, King's College London, and an MBA from Harvard University.

You can read the article on our LinkedIn page here.